title: Partial loss of genes might open therapeutic window.
abstract: The loss of genes that encode RNA splicing factors weakens cancer cells in a way that could be exploited by new approaches to treatment.
authors.affiliation: Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Bo
authors.identifier: 0000-0002-4511-6926
authors.initials: B
authors.lastname: Liu
authors.affiliation: Human Oncology and Pathogenesis Program and the Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Omar
authors.identifier: 0000-0002-3907-6171
authors.initials: O
authors.lastname: Abdel-Wahab
mesh_terms: D006801:Humans; D009369:Neoplasms; D010750:Phosphoproteins; D000072260:RNA Splicing Factors
chemical_list: D010750:Phosphoproteins; D000072260:RNA Splicing Factors; C112491:SF3B1 protein, human
keywords: CYCLOPS genes; SF3B1; cancer biology; cancer therapeutics; copy number alterations; human; human biology; medicine; mouse; spliceosome; target identification and validation